| Literature DB >> 32025969 |
Takashi Shiota1, Hideaki Kawanishi1, Satoki Inoue2, Junji Egawa1, Masahiko Kawaguchi1.
Abstract
INTRODUCTION: The use of both pulse oximetry (SpO2) and respiration rate (RR) monitoring is recommended to prevent the development of respiratory deterioration, particularly after extubation and narcotic analgesic use for pain management. In this study, we investigated the factors contributing to the development of bradypnea in surgical patients receiving fentanyl-based intravenous analgesia after general anesthesia.Entities:
Keywords: Acoustic monitoring; Bradypnea; Postoperative opioid; Postoperative respiratory deterioration; Respiratory rate monitoring
Year: 2018 PMID: 32025969 PMCID: PMC6967301 DOI: 10.1186/s40981-018-0186-x
Source DB: PubMed Journal: JA Clin Rep ISSN: 2363-9024
Fig. 1Study workflow. IV-fentanyl, fentanyl-based intravenous analgesia
Demographic and clinical characteristics and results of univariable logistic regression analyses for development of abnormal RRs
| Bradypnea ( | Normal RR ( | Odds | 95% CI | ||
|---|---|---|---|---|---|
| Age (year) | 63.1 (13.4) | 63.6 (13.3) | 0.973(/10 years) | 0.809–1.169 | 0.771 |
| Height (cm) | 157.9 (8.3) | 157.9 (10.2) | 1.130(/10 cm) | 0.753–1.537 | 0.976 |
| Weight (kg) | 57.2 (11.9) | 59.1 (12.9) | 0.841 (/10 kg) | 0.666–1.061 | 0.214 |
| Sex (F/M)a | 85/40 | 78/55 | 1.499 | 0.900–2.496 | 0.124 |
| BMI | 22. 9 (4.1) | 23.7 (4.5) | 1.004 | 0.992–1.017 | 0.149 |
| %VC | 107.2 (19.0) | 104.6 (17.6) | 1.082 (/10%) | 0.946–1.239 | 0.249 |
| FEV1.0% | 77.9 (10.0) | 79.5 (11.1) | 0.869 (/10%) | 0.686–1.102 | 0.245 |
| ASA status (I/II/III) | 30/87/8 | 23/98/12 | 0.703 | 0.435–1.135 | 0.344 |
| Surgical siteb | |||||
| Upper abdominal laparotomy | 13 | 10 | 0.831 | 0.309–2.231 | 0.731 |
| Lower abdominal laparotomy | 44 | 60 | 1.473 | 0.755–2.875 | 0.257 |
| Laparoscopic surgery | 41 | 38 | 1.001 | 0.497–2.017 | 0.998 |
| Orthopedic surgery | 27 | 25 | 1(reference) | 1 | 1 |
| Anesthesia (propofol/volatile)c | 36/89 | 43/90 | 0.847 | 0.498–1.440 | 0.590 |
| IV-fentanyl basal dose (μg/h) | 22.0 (7.3) | 22.6 (6.7) | 0.989 | 0.955–1.025 | 0.554 |
| PCA usage count | 1 [1–1] | 1 [1–1] | 1.142 | 0.742–1.759 | 0.546 |
| Fluid balance (ml) | 1850 [210–6142] | 1895 [− 450–7245] | 0.988(/100 ml) | 0.969–1.008 | 0.238 |
| Transfusion balance (ml) | −55 [− 1514–635] | −75 [− 2165–762] | 0.977(/100 ml) | 0.918–1.040 | 0.467 |
| Total fluid balance (ml) | 1740 [410–4702] | 1832 [− 500–6525] | 0.980(/100 ml) | 0.957–1.003 | 0.091 |
| Liver dysfunction (Y/N) | 25/100 | 13/120 | 2.308 | 1.122–4.745 | 0.023 |
| Renal dysfunction (Y/N) | 7/118 | 15/118 | 0.467 | 0.184–1.186 | 0.121 |
| Hypertension (Y/N) | 84/41 | 77/56 | 0.671 | 0.404–1.115 | 0.157 |
| Asthma (Y/N) | 2/123 | 2/131 | 1.065 | 0.148–7.678 | 1.000 |
| COPD (Y/N) | 9/116 | 5/128 | 1.986 | 0.647–6.098 | 0.277 |
| Hyperlipidemia (Y/N) | 8/117 | 14/119 | 0.581 | 0.235–1.437 | 0.270 |
| Diabetes mellitus (Y/N) | 15/110 | 18/115 | 0.871 | 0.418–1.814 | 0.852 |
| Ischemic heart disease (Y/N) | 5/120 | 6/127 | 0.882 | 0.262–2.966 | 1.000 |
| Heart failure (Y/N) | 1/124 | 1/132 | 1.065 | 0.066–17.204 | 1.000 |
| Smoking (Y/N) | 5/120 | 16/117 | 0.305 | 0.108–0.859 | 0.022 |
| Hemodialysis (Y/N) | 1/124 | 4/129 | 0.260 | 0.029–2.359 | 0.371 |
| Fentanyl 0 h (ng/ml) | 1.1 (0.3) | 1.1 (0.3) | 0.884 | 0.452–1.726 | 0.719 |
| Fentanyl 1 h (ng/ml) | 1.0 (0.2) | 1.0 (0.3) | 0.707 | 0.284–1.759 | 0.457 |
| Duration of surgery (min) | 204 [32–1202] | 241 [51–594] | 0.995(/10 min) | 0.978–1.012 | 0.336 |
| Duration of anesthesia (min) | 268 [81–1004] | 315 [89–712] | 0.986(/10 min) | 0.968–1.004 | 0.104 |
Bradypnea change was defined as an RR < 8 breaths per min in 2 min or longer
RR respiratory rate, BIM body mass index, %VC % vital capacity, FEV1.0% forced expiratory volume % in 1 s, Propofol propofol-maintained anesthesia, Volatile volatile anesthetics-maintained anesthesia, IV-fentanyl fentanyl-based intravenous analgesia, PCA patient-controlled analgesia, Total fluid balance fluid balance + transfusion balance, COPD chronic obstructive pulmonary disease, Fentanyl 0 h effect site concentrations of fentanyl at the end of surgery, Fentanyl 1 h effect site concentrations of fentanyl 1 h postoperatively
aMale sex is defined as the reference level
bOrthopedic surgery is defined as the reference level
cVolatile anesthetics is defined as the reference level
Results of multivariable logistic regression analyses for development of bradypnea
| Odds | 95% CI | ||
|---|---|---|---|
| Sexa | 1.401 | 0.796–2.464 | 0.242 |
| BMI | 0.949 | 0.889–1.013 | 0.114 |
| Total fluid balance | 0.990 (/100 ml) | 0.955–1.025 | 0.560 |
| Liver dysfunction | 2.918 | 1.329–6.405 | 0.008 |
| Renal dysfunction | 0.349 | 0.128–0.955 | 0.040 |
| Hypertension | 0.669 | 0.389–1.151 | 0.146 |
| Smoking | 0.236 | 0.075–0.735 | 0.013 |
| Duration of anesthesia | 0.995 (/10 min) | 0.967–1.024 | 0.739 |
| Fentanyl 0 h (ng/ml) | 1.467 | 0.337–6.379 | 0.610 |
| Fentanyl 1 h (ng/ml) | 0.442 | 0.052–3.780 | 0.456 |
BMI body mass index, Fentanyl 0 h effect site concentrations of fentanyl at the end of surgery, Fentanyl 1 h effect site concentrations of fentanyl 1 h postoperatively
aMale sex is defined as the reference level